Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN Study of brensocatib in non-cystic fibrosis bronchiectasis
NL-OMON54326Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brensocatib in bronchiectasis (3 arms), sponsored by Insmed Incorporated. Primary endpoint: Rate of adjudicated pulmonary exacerbations over the 52-week treatment period. Started Jul 2021; status: completed.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON54326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54326.